Facebook Twitter LinkedIn Google Plus RSS

Savient partnering with Swedish firm to market arthritis treatment

By ,

Savient Pharmaceuticals Inc., in Bridgewater, announced today it is partnering with Sobi, of Stockholm, to promote Kineret, a treatment for rheumatoid arthritis, in the United States.

Savient is a specialty biopharmaceutical company that has developed and commercialized the gout treatment Krystexxa, which it continues to market.

According to the announcement, Sobi has granted Savient the exclusive rights to co-promote the sale of Kineret with Sobi in the United States. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety and regulatory activities.




Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy